Phase 2 N=34 S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Overall Survival Rate — 31 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=165 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A
Severe Hemophilia A
Primary: Incidence Rate of FVIII Inhibitor Development — 0; 0; 0; 0 percentage of participants
N/A N=121 Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery
Orthostatic Hypotension · Hemodynamic Instability · Fever
Primary: Orthostatic Hypotension — 2; 2 participants
N/A N=571 Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome
Restless Legs Syndrome
Primary: Incidence of Drug-related Adverse Events — 76 participants
Phase 2 N=40 Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids
Uterine Fibroids
Primary: Change From Baseline in Vaginal Bleeding — -83.5; -36.0; -63.5; -39.5 mL
Phase 2 N=21 A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma
Relapsed, Refractory or Plateau Phase Multiple Myeloma
Primary: Response Rate [Complete Response (CR) and Partial Response (PR)] — 0; 0; 0; 1 participants
Phase 1 N=16 Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
Insomnia
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-∞) After Single Dose Suvorexant: Severe Renal Impairment Participants Versus…
Phase 3 N=26 Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial
Fibromyalgia · Neurocognition
Primary: Visual Analogue Scale for Pain — 59.4; 68.6; 58.5; 66.2 mm
Phase 2 N=109 A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
Migraine
Primary: Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the Treatment Period — 48.1; 48.9 percentage of participants — p=0.954
Phase 4 N=45 The Effect of Thoracic Epidural Anesthesia With Different Block Level on Propofol Induction
Target Controlled Infusion (TCI) · Thoracic Epidural Anesthesia · Block Level
Primary: The Effect-site Concentration of Propofol — 1.51; 1.99; 2.68 µg/ml
N/A N=168 Short Term Comparison of Two Different Techniques of Uterine Cesarean Incision Closure
Cesarean Section Complications
Primary: Cesarean Scar Defect in the Uterine Incisional Line — 12; 39 participants — p=0.0001
Phase 1 N=64 Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
Human Immunodeficiency Virus Type 1 (HIV-1)
Primary: Maximum Observed Plasma Concentration (Cmax) of Atazanavir — 3832; 4104; 2585; 2941 ng/mL
Phase 2 N=30 A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer
Liver Cancer
Primary: Progression-free Survival — 11.6 Months
N/A N=75 Compex Use With Delayed Onset Muscle Soreness: A Comparison to Other Methods
Focus of Study is to Determine Efficacy of Compex
Primary: Pain Scores on the Visual Analog Scale — 2.64; 2.60; 2.45; .80 scores on a scale
Phase 2 N=36 Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
Head and Neck Cancer
Primary: Response (Complete Response [CR] + Partial Response [PR]) — 6 participants